	US 7,414,059 B2
	Pyrazolyl and imidazolyl pyrimidines as CRF antagonists
Alam Jahangir, San Jose, Calif. (US); and Counde O'Yang, Sunnyvale, Calif. (US)
Assigned to Roche Palo Alto LLC, Palo Alto, Calif. (US)
Filed on Nov. 24, 2004, as Appl. No. 10/997,170.
Claims priority of provisional application 60/524547, filed on Nov. 24, 2003.
Prior Publication US 2005/0113382 A1, May 26, 2005
Int. Cl. C07D 403/04 (2006.01); A61K 31/506 (2006.01)

U.S. Cl. 514—256 [544/328]

19 Claims

1. A compound of the formula II:

or a pharmaceutically acceptable salt thereof, wherein:

X is 3-methylpyrazol-1-yl, 3,5- dimethylpyrazol-1-yl, 4-chloro-3,5-dimethylpyrazol-1-yl, 3-propylpyrazol-1-yl, 3- butyl-4-propylpyrazol-1-yl, 2-methylimidazol-1-yl, 4-methylimidazol-1-yl or 4- phenylimidazol-1-yl;

R^ais hydrogen or alkyl;

Z is alkyl;

R¹is hydrogen, alkyl, alkoxy, haloalkyl, halo, hydroxy, cyano, nitro, —NR^cR^d, —C(O)NR^cR^d, alkylcarbonyl or alkylsulfonyl wherein R^cand R^deach independently is hydrogen or alkyl;

m is 3; and

R²is halo.